Q1 Implantica

Interim Report January-March 2024

FINANCIAL SUMMARY

Figures within parentheses refer to the preceding year.

First Quarter

- Net sales increased 94% to TEUR 596 (307).
- Adjusted gross margin amounted to 92% (95%).
- Operating loss (EBIT) increased to TEUR 7,087 (4,870).
- Loss after tax amounted to TEUR 3,472 (4,758).
- Basic and diluted loss per Class A share amounted to EUR 0.05 (0.07).
- Cash as at the end of the period amounted to MEUR 80.1.

Significant Events

IN THE FIRST QUARTER OF 2024

- Submitted Premarket Approval (PMA) application for RefluxStop™ to U.S. FDA.
  - First of three modules submitted
  - Next two modules to be submitted in estimated 2 three-month intervals
  - One time costs of EUR 2.5 million attributed to the FDA process including the Usability study during Q1
- Completed Human Factors Validation Study with 16 U.S. surgeons as part of the FDA PMA process.
- 20 U.S. foregut surgeons trained on the RefluxStop procedure in preparation for the Usability Study, a very successful U.S. pre-launch activity.
- First-ever public tender win for RefluxStop™ in Italy achieved by Ospedale di Moncalieri Turin.
  - 3-year public tender, funded to full list price by the public healthcare system
- Second public hospital purchase agreement win in Italy at IRCCS Saverio De Bellis in Bari, Italy to buy the RefluxStop™ devices to full price.
- Norway opened as a new country performing RefluxStop™. First five surgeries successfully performed at Akershus University Hospital in Oslo.

AFTER THE END OF THE PERIOD

- First in the country public tender win in Spain for RefluxStop™ at Hospital Universitario de Getafe, a public hospital in Madrid.
- Landmark, >25 hospitals in our target markets in Europe successfully operating with RefluxStop™.
- Six scientific presentations and abstracts presented at the 2024 SAGES annual scientific meeting in Cleveland, Ohio.
- Two peer-reviewed scientific papers published on real-world RefluxStop™ results by Dr. Joerg Zehetner on large hiatal hernia patients and those with ineffective esophageal motility.

REFLUXSTOP™ ON PATH TO BECOME STANDARD OF CARE FOR ACID REFLUX TREATMENT

Becoming standard of care in a market of 1 billion sufferers would be an exceptional achievement. Implantica is building this case step by step and gaining U.S. approval, based on our PMA submission, would likely heavily influence such an outcome.

The first quarter of 2024 was a period of exceptional progress for Implantica, marked by critical milestones in our journey to make RefluxStop™ the new standard of care for gastroesophageal reflux disease (GERD). I am excited to share some of the key developments that have unfolded during and after this quarter.

FDA Premarket Approval (PMA) process

The submission of our U.S. FDA Premarket Approval (PMA) application, starting with the first module was the most significant accomplishment during the first quarter. According to the plan agreed with the FDA (Food & Drug Administration), we will submit the second and third modules at approximately three-month intervals this year, demonstrating our commitment to gaining regulatory approval and expanding into the US market. This advancement represents a crucial step in our mission to provide RefluxStop™ to a broader audience.

Human Factors Validation Study in Chicago

In support of the PMA process, we completed a Human Factors Validation Study at Northwestern University's Simulation Lab in Chicago with 16 U.S. surgeons. This study was designed to evaluate how surgeons from various backgrounds and experience levels performed the RefluxStop™ procedure, further validating our technique and demonstrating its potential for wide adoption across the U.S.

An independent third party is now evaluating the data collected during the usability study and the findings will be included in the next module of the PMA submission to FDA. In preparation for the study, 20 foregut surgeons from more than 10 prominent U.S. hospitals participated in the RefluxStop™ standardized surgery training program.

We believe this will advance the widespread availability of RefluxStop™ in the U.S. once market approval is achieved.

An estimated 27% of the adult population struggle with GERD and 40% of GERD patients do not respond to PPIs,

CEO - Peter Forsell

the most common medication to treat this disease. This means the market opportunity in the U.S. is nothing less than enormous.

Expansion and growth

Our expansion efforts continue to bear fruit, and currently, over 25 hospitals are regularly performing the RefluxStop™ procedure, with the total number of RefluxStop™ procedures reaching more than 750.

This growing base of RefluxStop™ users underscores the strong acceptance and adoption of our technology among healthcare professionals. This said once full reimbursement is achieved, the business is expected to take off in a different magnitude.

Public tender wins, hospital agreements

We are pleased to announce the first-ever public tender win for RefluxStop™ in Italy with Ospedale di Moncalieri in Turin. This three-year public tender provides coverage for the full list price of EUR 5,900 for each RefluxStop™ device. Additionally, we secured a second public hospital purchase agreement win in Italy with IRCCS Saverio De Bellis in Bari, Puglia, allowing the hospital to buy up to 36 RefluxStop™ devices at full price. Further, we achieved a first-in-the-country public tender win in Spain with Hospital Universitario de Getafe in Madrid.

This is just the beginning - a great start to achieving general reimbursement by the healthcare systems in Europe. With a growing number of local or regional funding approvals by healthcare systems across Europe, these milestones will directly support future national reimbursement outcomes in more countries.

Surgical successes and partnerships

The first RefluxStop™ surgeries were performed at Akershus University Hospital in Oslo, Norway, where five patients were successfully operated on by two prominent Norwegian surgeons.

In the UK, the NICE (National Institute for Health and Care Excellence) review process is advancing through their Interventional Procedures Advisory Committee (IPAC). The NICE IPAC guidance decision will play a pivotal role in NHS public hospitals adopting our technology. More than 50 RefluxStop™ procedures have been successfully completed across three UK hospitals, with another NHS hospital having joined the centers offering RefluxStop™ at the end of April 2024.

New clinical and scientific advancements

In France, we completed a key alignment with a French market access and HAS strategy expert, finalizing a new randomized clinical trial design and protocol to support achieving reimbursement in the Franch healthcare system.

At the 2024 SAGES (Society of American Gastrointestinal and Endoscopic Surgeons) annual scientific meeting in Cleveland, Ohio, we presented multiple scientific presentations and abstracts, showcasing the clinical outcomes of the CE study on RefluxStop™ over four years, among other notable results.

- Real-world clinical data from over 200 patients and across another five RefluxStop™ centers in Europe presented
- Largest conference in the world dedicated specifically to gastrointestinal and endoscopic surgery

Additionally, two peer-reviewed scientific papers on real-world RefluxStop™ results were published in reputed medical journals:

- Surgical Laparoscopy Endoscopy & Percutaneous Techniques (SLEPT) on large hiatal hernia patients
- Langenbaeck's Archives of Surgery on patients with ineffective esophageal motility

Overall, Implantica's progress during and after the first quarter has been significant, and we remain focused on expanding our commercial footprint in Europe and obtaining FDA approval for the US market. The acceptance of RefluxStop™ within public healthcare systems and the growing body of clinical evidence and peer-reviewed publications underscore the value and efficacy of our solution and long-term strategic plan to best build a substantial business with our unique device, RefluxStop™.

eHealth platform

Implantica has developed an eHealth- and wireless energising-platform covered by >25'000 pages of patent applications. Part of the resources for our eHealth platform has temporarily been moved to our launch plan for RefluxStop™ in the U.S. However, this eHealth technology provides a cornerstone in Implantica's future growth, developed to be used with a majority of our large pipeline products. eHealth will likely revolutionise healthcare in the future.

Acid reflux causes Cancer

Society tries to save any cancer life, which is best visualized in large breast cancer prevention programs, however, in our treatment field 48'000 people die annually from esophageal adenocarcinoma in the EU and U.S. alone. This is a totally unacceptable situation and RefluxStop™ has all the attributes to potentially change this situation.

Thank you for your continued support and partnership as we work to bring RefluxStop™ to a broader audience and make a lasting impact on the lives of those suffering from acid reflux.

Yours sincerely,

Dr. med. Peter Forsell
CEO and Founder, Implantica
Surgeon and Inventor

IMPLANTICA IN BRIEF

Implantica is a MedTech group committed to providing effective care for serious health conditions and improving patient quality of life by bringing advanced technology into the body. Simultaneously, Implantica aims to reduce overall costs and improve efficiency in the healthcare system.
The therapies Implantica develops are based on implants, which are inserted into the patient's body to replace bodily functions and/or treat diseases. Implantica has developed two platform technologies to be able to bring smart medical implants into the body.
Bringing advanced technology into the body requires enough power to activate a device inside the body long-term, which is the reason why a wireless energising platform has been developed. In addition, the Company has developed an eHealth platform for communicating with and reprogramming implants.
These platform technologies are covered by a multitude of patents and patent applications.
Implantica has developed a broad, patent protected, product pipeline, two-thirds of which is based on their two platform technologies.
Implantica's most progressed product, RefluxStop™, represents a potential paradigm shift in the treatment of GERD. Acid reflux has a significant impact on patient quality of life and can induce serious complications, including increased risk for oesophageal cancer.
GERD patients rely today, to a large extent, on PPIs – a drug therapy which calms symptoms of GERD. Ultimately, with PPI treatment reflux is not prevented and the risk for oesophageal cancer remains according to a report from Karolinska Institute. Alternative surgical procedures available today are plagued with complications, including compression of the food passageway and swallowing difficulties.

Top ten shareholders as of 31 March 2024

Name	Capital (%)
Peter Forsell	47.4%
Handelsbanken Fonder	8.8%
EFG Bank	7.2%
TIN Fonder	2.9%
Avanza Pension	2.5%
SEB Life	2.4%
UBP	2.2%
UBS	1.7%
SIX SIS AG	1.5%
Stephan Siegenthaler	1.3%

Financial performance in brief

Figures in parentheses within the following section refer to the corresponding period in the preceding year.

Net sales

During the first quarter, net sales amounted to EUR 596 thousand (307), corresponding to an increase of EUR 289 thousand or 94%. Implantica is currently exclusively marketing its lead product, RefluxStop™, to selected Key Opinion Leaders in Europe.

Cost of sales and gross margin

Cost of sales during the first quarter amounted to EUR 355 (323) thousand. Cost of sales considers two categories of costs. Firstly, indirect costs of straight-line amortisation of capitalised development costs relating to RefluxStop™. Secondly, Other cost of sales, which relates to direct costs for purchasing goods and services from the Group's outsourcing partners.

In the first quarter, adjusted gross margin[1], i.e., gross margin excluding amortization, amounted to 92% (95%).

Operating expenses and EBIT

In the first quarter, operating loss (EBIT) amounted to EUR 7,087 thousand (4,870), an increase of EUR 2,217 thousand or 46%. Research and development costs made up EUR 4,327 thousand (1,824), corresponding to an increase of EUR 2,503 thousand or 137%.

The increase of research and development costs is primarily driven by costs relating to the FDA submission over the quarter including a usability study. The expensed and capitalized costs relating to pipeline products and the eHealth platform were materially lower than in the first quarter of 2023.

General and administrative costs amounted to EUR 3,000 thousand (3,030), a decrease of EUR 30 thousand or 1%.

Financial income and expenses

Financial income amounted to EUR 3,637 thousand (513) during the first quarter thanks to foreign exchange gains and interest income. Financial expenses amounted to EUR 20 thousand (412) over the quarter driven by foreign exchange losses.

Income taxes

The Group reported a tax expense of EUR 2 thousand (-11) in the first quarter. The tax expense for the quarter is mainly explained by changes in deferred tax assets.

Net earnings

The Group reported a net loss of EUR 3,472 thousand (4,758) for the first quarter, a decrease of EUR 1,286 thousand.

Equity and liabilities

As of 31 March 2024, the Group's equity amounted to EUR 117.0 million (138.2) and the equity ratio was 96%, compared to 97% at 31 March 2023.

As of 31 March 2024, the Group did not have any interest-bearing debt.

Cash flow and liquidity

During the first quarter, net cash outflow from operating activities amounted to EUR 6,465 thousand (4,257).

As of 31 March 2024, Implantica held cash and cash equivalents of EUR 80.1 million.

Auditor's review

This report has not been reviewed by the company's auditors.

[1] Adjusted gross profit as a percentage of Net sales. Where Adjusted gross profit is defined as Net sales minus cost of sales, plus amortization of development costs.

Consolidated interim financial statements

Condensed consolidated statement of profit or loss

	Jan to Mar		Jan to Dec
in thousands of EUR	2024	2023	2023
Net Sales	596	307	1'408
Cost of sales			
Amortisation of capitalized development costs	(307)	(307)	(1'227)
Other cost of sales	(49)	(16)	(90)
Total cost of sales	(356)	(323)	(1'317)
Gross profit/(loss)	240	(16)	91
Other income	-	-	33
Research and development costs (Note 4)	(4'327)	(1'824)	(7'016)
General and administrative costs	(3'000)	(3'030)	(14'948)
Operating loss	(7'087)	(4'870)	(21'840)
Financial income	3'637	513	701
Financial expenses	(20)	(412)	(3'289)
Loss before income taxes	(3'470)	(4'769)	(24'428)
Income taxes	(2)	11	(74)
Loss for the period	(3'472)	(4'758)	(24'502)
Attributable to			
Owners of Implantica AG	(3'364)	(4'552)	(23'744)
Non-controlling interests	(108)	(206)	(758)
Loss for the period	(3'472)	(4'758)	(24'502)
Earnings per share (Note 5)			
Basic and diluted loss per share Class A (in EUR)	(0.05)	(0.07)	(0.34)
Basic and diluted loss per share Class B (in EUR)	(0.00)	(0.00)	(0.00)

Condensed consolidated statement of profit or loss and other comprehensive income

	Jan to Mar		Jan to Dec
in thousands of EUR	2024	2023	2023
Loss for the period	(3'472)	(4'758)	(24'502)
Other comprehensive income			
Remeasurement of net defined benefit liability	(76)	18	(296)
Related income taxes	-	(2)	36
Total items that will not be reclassified to profit or loss	*(76)*	*16*	*(260)*
Translation differences (Note 6)	(4'534)	(1'207)	5'593
Total items that may be reclassified subsequently to profit or loss	*(4'534)*	*(1'207)*	*5'593*
Other comprehensive income for the period, net of tax	(4'610)	(1'191)	5'333
Total comprehensive income for the period	(8'082)	(5'949)	(19'169)
Attributable to			
Owners of Implantica AG	(7'974)	(5'744)	(18'411)
Non-controlling interests	(108)	(205)	(758)
Total comprehensive income for the period	(8'082)	(5'949)	(19'169)

Condensed consolidated statement of financial position

in thousands of EUR	31 Mar 2024	31 Mar 2023	31 Dec 2023
ASSETS			
Current assets			
Cash and cash equivalents	80'082	102'331	87'922
Accounts receivable	453	148	432
Other current receivables	1'495	810	989
Inventories	214	158	311
Total current assets	82'244	103'447	89'654
Non-current assets			
Property, plant and equipment	245	238	273
Right-of-use assets	757	1'040	874
Intangible assets (Note 4)	37'894	36'758	38'163
Deferred tax assets	986	988	987
Total non-current assets	39'882	39'024	40'297
Total assets	122'126	142'471	129'951
LIABILITIES AND EQUITY			
Current liabilities			
Trade accounts payables	29	-	-
Financial liabilities	294	317	314
Financial liabilities due to ultimate main shareholder	1	27	1
Other current liabilities	3'681	2'900	3'431
Total current liabilities	4'005	3'244	3'746
Non-current liabilities			
Financial liabilities	486	740	584
Pension liability	614	270	575
Total non-current liabilities	1'100	1'010	1'159
Total liabilities	5'105	4'254	4'905
Equity			
Share capital (Note 6)	129'137	129'137	129'137
Capital reserves	370'548	370'548	370'548
Treasury share reserve (Note 6)	(2)	(20)	(2)
Translation differences (Note 6)	11'113	8'846	15'647
Retained earnings	(391'442)	(368'622)	(388'059)
Total equity attributable to owners of Implantica AG	119'354	139'889	127'271
Non-controlling interests	(2'333)	(1'672)	(2'225)
Total equity	117'021	138'217	125'046
Total liabilities and equity	122'126	142'471	129'951

Condensed consolidated statement of cash flows

in thousands of EUR	Jan to Mar 2024	Jan to Mar 2023	Jan to Dec 2023
Loss for the period	(3'472)	(4'758)	(24'502)
Adjustments for			
Depreciation, amortisation and impairment	410	401	1'624
Financial income	(3'637)	(513)	(701)
Financial expenses	20	412	3'289
Income taxes	2	(11)	74
Share-based compensation	57	99	187
Other financial result	(5)	(5)	(45)
Change in pension liabilities	(6)	24	(18)
Other non-cash items	(100)	10	(84)
Changes in net working capital			
Decrease / (increase) accounts receivable	(21)	(60)	(344)
Decrease / (increase) other current receivables	(506)	56	(123)
Decrease / (increase) inventories	97	8	(145)
(Decrease) / increase trade payables	29	-	-
(Decrease) / increase other current liabilities	667	80	880
Net cash outflow from operating activities	(6'465)	(4'257)	(19'908)
Cash flows from investing activities			
Purchase of property, plant and equipment	-	(14)	(87)
Investment in intangible assets (Note 4)	(471)	(1'137)	(3'742)
Interest received	107	96	675
Net cash inflow/(outflow) from investing activities	(364)	(1'055)	(3'154)
Cash flows from financing activities			
Treasury shares acquired	-	(20)	(59)
Payment of lease liabilities	(75)	(81)	(305)
Interest paid	(6)	-	(27)
Repayment of financial liabilities	-	(14)	(40)
Net cash outflow from financing activities	(81)	(115)	(431)
Net increase/(decrease) in cash and cash equivalents	(6'910)	(5'427)	(23'493)
Effect of exchange rate fluctuations on cash held	(930)	(1'193)	2'464
Cash and cash equivalents at beginning of period	87'922	108'951	108'951
Cash and cash equivalents at end of period	80'082	102'331	87'922

Condensed consolidated statement of changes in equity

in thousands of EUR	Jan to Mar 2024							
	Share capital	Capital reserves	Treasury share reserve	Translation differences	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 31 December 2023	129'137	370'548	(2)	15'647	(388'059)	127'271	(2'225)	125'046
Loss for the period attributable to owners of the Company	-	-	-	-	(3'364)	(3'364)	(108)	(3'472)
Other comprehensive income (net)	-	-	-	(4'534)	(76)	(4'610)	-	(4'610)
Total comprehensive income (net)	-	-	-	(4'534)	(3'440)	(7'974)	(108)	(8'082)
Share-based compensation	-	-	-	-	57	57	-	57
Total transactions with shareholders	-	-	-	-	57	57	-	57
Balance at 31 March 2024	129'137	370'548	(2)	11'113	(391'442)	119'354	(2'333)	117'021

in thousands of EUR	Jan to Mar 2023							
	Share capital	Capital reserves	Treasury share reserve	Translation differences	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 31 December 2022	129'137	370'548	-	10'054	(364'185)	145'554	(1'467)	144'087
Loss for the period attributable to owners of the Company	-	-	-	-	(4'552)	(4'552)	(206)	(4'758)
Other comprehensive income (net)	-	-	-	(1'208)	16	(1'192)	1	(1'191)
Total comprehensive income (net)	-	-	-	(1'208)	(4'536)	(5'744)	(205)	(5'949)
Treasury shares acquired	-	-	(20)	-	-	(20)	-	(20)
Share-based compensation	-	-	-	-	99	99	-	99
Total transactions with shareholders	-	-	(20)	-	99	79	-	79
Balance at 31 March 2023	129'137	370'548	(20)	8'846	(368'622)	139'889	(1'672)	138'217

Notes

NOTE 1 General information

Implantica AG (the 'Company') is domiciled at Aeulestrasse 45, 9490 Vaduz, Liechtenstein. These condensed consolidated interim financial statements ('interim financial statements') as at and for the three months ended 31 March 2024 comprise the Company and its subsidiaries (together referred to as the 'Group'). The Group is primarily involved in the research and distribution of medical implants. Implantica AG was admitted to trading on the Nasdaq First North Premier Growth Market in Stockholm in September 2020. Implantica AG is ultimately controlled by the Implantica Founder, Dr. Peter Forsell.

These interim financial statements were authorised for issue by the Company's Board of Directors on 14 May 2024. As of this date, no material events after the reporting date have occurred.

NOTE 2 Summary of significant accounting policies

Basis of preparation

These interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with the Group's consolidated financial statements as at and for the year ended 31 December 2023 ('last financial statements'). These interim financial statements do not include all of the information required for a complete set of financial statements prepared in accordance with IFRS. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last financial statements.

For the preparation of these financial statements the historical cost basis except for all those assets and liabilities measured at fair value has been applied. All amounts are presented in EUR, and are rounded to the nearest thousand of EUR with the consequence that the rounded amounts may not add to the rounded total in all cases. All ratios and variances are calculated using the underlying amounts rather than the rounded amounts.

Critical accounting estimates and judgements

In preparing these interim financial statements, management has made judgements and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

NOTE 3 General accounting policies

The accounting policies applied in these interim financial statements are the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 December 2023.

There were no new standards or amendments to existing standards that have a material effect on the Group's interim financial statements.

NOTE 4 Intangible assets

	Jan to Mar	
in thousands of EUR	2024	2023
Net carrying amount at 1 January	38'163	35'977
Additions Jan to Mar	54	1'090
Amortization Jan to Mar	(318)	(309)
Translation differences	(5)	-
Net carrying amount at 31 March	37'894	36'758

For the first quarter Research and development costs in the amount of EUR 4'327 thousand were recognised in profit or loss since the conditions for capitalisation as intangible assets for these costs are not met.

NOTE 5 Earnings per share

	Jan to Mar		Jan to Dec
in thousands of EUR	2024	2023	2023
Loss for the period attributable to owners of Implantica AG	(3'364)	(4'552)	(23'744)
Weighted average % of Class A share capital in total share capital	83.8%	83.8%	83.8%
Weighted average % of Class B share capital in total share capital	16.2%	16.2%	16.2%
Class A shares			
Loss for the period attributable to Class A shareholders	(2'818)	(3'814)	(19'892)
Weighted average number of outstanding Class A shares	58'110'245	58'111'453	58'090'580
Basic and diluted (loss) per share Class A (in EUR)	(0.05)	(0.07)	(0.34)
Class B shares			
Loss for the period attributable to Class B shareholders	(546)	(738)	(3'852)
Weighted average number of Class B shares	1'125'000'000	1'125'000'000	1'125'000'000
Basic and diluted (loss) per share Class B (in EUR)	(0.00)	(0.00)	(0.00)

Earnings per category of shares

Earnings per class of shares (Note 6) are calculated on the basis of the net loss attributable to the shareholders of Implantica AG based on their portion of the share capital and the average number of outstanding shares (i.e. excluding treasury shares).

Anti-dilutive effect of potential outstanding shares

The impact of share-based compensation arrangements was not considered in the diluted earnings per share calculation for Class A shares for the three months ended 31 March 2024 and 2023 because due to the net loss for these periods their effect would have been anti-dilutive.

NOTE 6 Equity

Share capital

The fully paid in share capital of the Group amounts to CHF 138,723 thousand (EUR 129,137 thousand) and is divided into 58,111,537 registered shares with a nominal value of CHF 2.00 each (Class A) and 1,125,000,000 with a nominal value of CHF 0.02 each (Class B).

During the period the number of shares remained unchanged.

Translation differences

During the three months ended 31 March 2024 the EUR/CHF exchange rate decreased from 1.080 to 1.024. As a result, the group recognised a total loss of EUR 4,534 thousand in other comprehensive income related to the translation of financial statements of foreign operations and net investments in foreign operations.

Other

Telephone conference

Implantica will hold a teleconference on 15 May 2024 at 15:00 (CEST) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:

Webcast

https://ir.financialhearings.com/implantica-q1-report-2024

Dial-in

Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference.

https://conference.financialhearings.com/teleconference/?id=50049901

Financial calendar

22 May 2024	Annual General Meeting
21 August 2024	Interim Report Q2 2024
15 November 2024	Interim Report Q3 2024

Listing

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm. The company is traded under the ticker symbol IMP A SDB and ISIN code SE0014855029.

Disclaimer statement

Some statements herein are forward-looking, and the actual outcome could be materially different. In addition to the factors explicitly commented upon, the actual outcome could be materially affected by other factors, for example: the impact of undesired side effects related to existing or future products, failures in handling of the quality system, obstacles in obtaining CE and FDA approvals and re-certifications, products may fail to become subject to insurance and reimbursement policies and risk not gaining widespread acceptance, clinical trials may prove to be unsuccessful and the impact of competing products.

Contacts

Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone: +41 (0)79 335 09 49
E-mail: nicole.pehrsson@implantica.com

Peter Forsell, CEO
Telephone: +423 376 6066 (switchboard)
E-mail: peter.forsell@implantica.com

Andreas Öhrnberg, CFO
Telephone: +423 376 6066 (switchboard)
E-mail: andreas.oehrnberg@implantica.com

Implantica AG
Aeulestrasse 45
9490 Vaduz
Liechtenstein

www.implantica.com